🔎 Trials Near Me

Home › Burkitt Lymphoma › New York › New York City

Burkitt Lymphoma clinical trials in New York City, NY

13 studies for Burkitt Lymphoma are looking for participants at sites in and around New York City (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

RecruitingPhase 3
  • Memorial Sloan Kettering Cancer Center, New York
Ages 1 and older · All sexes · Updated Oct 5, 2026 · NCT07223021

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

RecruitingPhase 2
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
  • Memorial Sloan Kettering Cancer Center, New York
  • and 1 more
366 Days – 46 Years · All sexes · Updated Oct 2, 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

RecruitingPhase 3
  • Mount Sinai Hospital, New York
  • NYP/Weill Cornell Medical Center, New York
Ages 18 to 39 · All sexes · Updated Oct 2, 2026 · NCT03150693

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

RecruitingPhase 2
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
  • Memorial Sloan Kettering Cancer Center, New York
  • NYP/Weill Cornell Medical Center, New York
365 Days · All sexes · Updated Sep 25, 2026 · NCT06317662

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

RecruitingPhase 1/2
  • Memorial Sloan Kettering Cancer Center ( Site 1010), New York
6 Months – 25 Years · All sexes · Updated Sep 17, 2026 · NCT06395103

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

RecruitingPhase 1
  • Columbia University Irving Medical Center/New York Presbyterian Hospital, New York
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT03666000

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

RecruitingPhase 2
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
  • Memorial Sloan Kettering Cancer Center, New York
  • NYP/Weill Cornell Medical Center, New York
Ages 1 to 30 · All sexes · Updated Sep 1, 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

RecruitingPhase 3
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
  • Mount Sinai Hospital, New York
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
  • and 2 more
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

RecruitingPhase 1/2
  • Research Site, New York
Ages 12 and older · All sexes · Updated Aug 19, 2026 · NCT06137118

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

RecruitingPhase 2
  • Memorial Sloan Kettering Cancer Center, New York
Ages 18 to 54 · All sexes · Updated Mar 17, 2026 · NCT06918431

Study of SGR-1505 in Mature B-Cell Neoplasms

RecruitingPhase 1
  • Weill Cornell, New York
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05544019

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

RecruitingPhase 1/2
  • Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
Ages 15 to 50 · All sexes · Updated Sep 9, 2025 · NCT04150497

Burkitt Lymphoma trials in other cities

Other studies in New York City

From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.